In a nutshell The authors investigated the health-related quality of life (HRQoL) 1 year after the diagnosis of diffuse large B-cell lymphoma (DLBCL). The study found that HRQoL is affected differently in women and men survivors of DLBCL 1 year after diagnosis and that aspects of HRQoL need to be addressed and managed in these...Read More
Current disease status-First occurrence of the lymphoma Posts on Medivizor
Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma
In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL). This study concluded that this treatment combination was safe and effective in these patients. Some background HL is a common cancer...Read More
Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL
In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...Read More
Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?
In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...Read More
Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.
In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...Read More
Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...Read More
How effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?
In a nutshell This study compared the BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide) and IEAC (idarubicin, etoposide, cytarabine, and cyclophosphamide) regimens before autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (r/r) and aggressive B-cell non-Hodgkin lymphoma (NHL). The study found that IEAC regimen...Read More
Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?
In a nutshell The aim of this study was to evaluate high-dose (HD) methotrexate (MTX; Trexall) alone and in combination with other therapies for the treatment of primary central nervous system (CNS) lymphoma (PNCSL). The study found that HD-MTX in combination with other chemotherapies was most effective for these patients. Some background...Read More
In a nutshell This review aimed to compare the safety and effectiveness of first-line treatments for mantle cell lymphoma. The authors concluded that newer treatments improve outcomes for younger transplant eligible patients and elderly transplant-ineligible patients. Some background Mantle cell lymphoma (MCL) is a rare form...Read More
Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy
In a nutshell This study investigated different rituximab schedules in patients with follicular lymphoma (FL) and reported their long-term treatment outcomes. The data showed that rituximab treatment alone on a standard schedule improves the long-term outcomes of these patients. Some background Follicular lymphoma (FL) is a type of non-Hodgkin...Read More
Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country
In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...Read More
In a nutshell This study was carried out to assess the outcomes of pregnant women who have non-Hodgkin lymphoma (NHL). The authors concluded that treating NHL with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens during pregnancy can be considered after the first trimester. Some background NHL...Read More